Early Trial Shows Stool Capsules May Boost Peanut Allergy Tolerance
A phase-one study found that six adults with peanut allergy tolerated small peanut exposures for up to four months after receiving fecal microbiome transplants in capsule form.
Researchers administered oral stool capsules to six participants diagnosed with peanut allergy and observed increased resistance to minor peanut challenges for as long as four months. The findings were published in Science Translational Medicine and suggest that fecal microbiome transplantation could become a therapeutic option. Experts in the allergy field called the results promising, though they cautioned that further research is needed before clinical use.
Why it matters
It hints at a novel, microbiome-based way to treat peanut allergies, a common and potentially life-threatening condition.
In this story